Image 1 of 1
Tego Science Inc.
BBIU Intelligence Report: Tego Science Inc. (July 2025)
Category: Full Due Diligence Briefing | Language: English | Length: 8 Pages | Format: PDF (Available in Spanish/Korean upon request)
Executive Summary for Strategic Buyers and Investors:
This report offers a precision-grade assessment of Tego Science Inc., one of South Korea’s leading cell therapy players (KOSDAQ: 191420), focused on regenerative medicine for dermatology and orthopedics. The analysis goes beyond surface-level metrics to dissect:
📊 Ownership Reality – Full equity breakdown by name and family ties
💰 Financial Health – Revenue, loss structures, R&D loading, and cash runway
🧪 Clinical Pipeline Deep-Dive – TPX-115 Phase 2b/3 rotator cuff trial, Phase 1 data, and U.S. IND status
🔏 IP Intelligence – Active vs. pending patents, jurisdictional spread, regenerative claims
📉 Strategic Risks – Kaloderm dependency, negative EBITDA, single-client CDMO exposure
🌏 Competitive Mapping – First-mover advantage vs. Medipost, Corestem, Kangstem
💼 VC Lens – What must happen before Tego is globally viable (licensing, milestones, scalability triggers)
The report adheres to BBIU’s 5 Laws of Operational Intelligence (Truthfulness, Source Referencing, Reliability, Context, Traceability), ensuring each claim is evidence-anchored and decision-grade. It includes direct references from official Korean filings, clinical trial registries, and USPTO records.
Ideal for:
✅ Cross-border VC firms exploring APAC cell therapy assets
✅ Buy-side biotech analysts screening licensing targets
✅ Mid-sized pharma evaluating dermal/cellular verticals
✅ Strategic consultants vetting partnership risks
Access Password
This document is password-protected.
To open it, use the company’s stock exchange ID number as the password.
🔐 Example: 6 digit
If you encounter any issues, contact us at yoonhwa.an@biopharmabusinessintelligenceunit.com
BBIU Intelligence Report: Tego Science Inc. (July 2025)
Category: Full Due Diligence Briefing | Language: English | Length: 8 Pages | Format: PDF (Available in Spanish/Korean upon request)
Executive Summary for Strategic Buyers and Investors:
This report offers a precision-grade assessment of Tego Science Inc., one of South Korea’s leading cell therapy players (KOSDAQ: 191420), focused on regenerative medicine for dermatology and orthopedics. The analysis goes beyond surface-level metrics to dissect:
📊 Ownership Reality – Full equity breakdown by name and family ties
💰 Financial Health – Revenue, loss structures, R&D loading, and cash runway
🧪 Clinical Pipeline Deep-Dive – TPX-115 Phase 2b/3 rotator cuff trial, Phase 1 data, and U.S. IND status
🔏 IP Intelligence – Active vs. pending patents, jurisdictional spread, regenerative claims
📉 Strategic Risks – Kaloderm dependency, negative EBITDA, single-client CDMO exposure
🌏 Competitive Mapping – First-mover advantage vs. Medipost, Corestem, Kangstem
💼 VC Lens – What must happen before Tego is globally viable (licensing, milestones, scalability triggers)
The report adheres to BBIU’s 5 Laws of Operational Intelligence (Truthfulness, Source Referencing, Reliability, Context, Traceability), ensuring each claim is evidence-anchored and decision-grade. It includes direct references from official Korean filings, clinical trial registries, and USPTO records.
Ideal for:
✅ Cross-border VC firms exploring APAC cell therapy assets
✅ Buy-side biotech analysts screening licensing targets
✅ Mid-sized pharma evaluating dermal/cellular verticals
✅ Strategic consultants vetting partnership risks
Access Password
This document is password-protected.
To open it, use the company’s stock exchange ID number as the password.
🔐 Example: 6 digit
If you encounter any issues, contact us at yoonhwa.an@biopharmabusinessintelligenceunit.com